Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

71.91 -1.48 (-2.02%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Monopar Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

November 14, 2025

Via Benzinga

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 13, 2025

Via Benzinga

Recap: Monopar Therapeutics Q4 Earnings ↗

March 28, 2024

Via Benzinga

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗

September 15, 2025

The company is working on a treatment for a rare, inherited disease that causes copper to build up in the body.

Via Investor's Business Daily

This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 20, 2024

Via Benzinga

3 Momentum Stocks Soaring Into 2025 and Beyond

December 03, 2024

Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.

Via MarketBeat

Topics Stocks

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 28, 2024

Via Benzinga

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

October 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

What's Going On With Monopar Therapeutics Shares Friday? ↗

October 25, 2024

Monopar entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 for Wilson disease.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 25, 2024

Via Benzinga

Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

October 25, 2024

Via Benzinga

Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 24, 2024

The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.

Via Benzinga

Topics Stocks

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder ↗

October 24, 2024

Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 01, 2024

Via Benzinga

Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today ↗

September 12, 2024

Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.

Via Benzinga

MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 ↗

August 09, 2024

MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗

June 24, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 07, 2024

Via Benzinga

Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely ↗

June 05, 2024

Penny stocks are risky. It’s why we attach a warning to the tail-end of penny stock articles and why the SEC has a warning about them too.

Via InvestorPlace

Topics Regulatory Compliance

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗

June 03, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 09, 2024

Via Benzinga

MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 ↗

May 09, 2024

MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 03, 2024

Via Benzinga

MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 ↗

March 28, 2024

MNPR stock results show that Monopar Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.